Bachem - What does it take to manufacture oligonucleotides

Looking for more info about future trends in oligonucleotides Listen to the podcast and hear Daniel Samson share his industry insight.

He discusses capacity, scalability, cost-effectiveness, time-to-market, sustainability, and the trend toward increasingly complex oligonucleotide-based drugs.

Oligonucleotides have emerged as a new drug modality originally targeting rare diseases. Today, they are delivering on their promise, showing their potential for common diseases that affect a larger number of patients. Bachem recognized this shift and the need to manufacture oligonucleotides on a large scale to meet the market demand. Daniel Samson, Head Oligonucleotides at Bachem, explained that 'by nature, rare diseases were the first targets, but we see more and more trends towards larger indications, larger populations. This generates a lot more demand, and more capacity is needed. In addition, big pharma companies are getting more and more excited. So, that's certainly a trend. We'll have both rare diseases of small indications, but also large indications.'

The company saw an opportunity to expand its existing manufacturing capacity and expertise in large-scale active pharmaceutical ingredients (APIs) by building facilities to produce oligonucleotide APIs. However, this change in scale and high demand bring new challenges related to capacity, sustainability, supply chain, cost, and quality.

Bachem recognizes this and is meeting these challenges with investments in new facilities, people, and innovations. With our expertise in peptide drug development and commercialization, we have been able to exploit synergies in technology and know-how. As a first mover in the industry, we are pioneering the implementation of automation, new methods, and technologies for synthesis and purification, such as continuous chromatography on a commercial scale.

ABOUT BACHEM

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.

With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

Contact:

Tel: [phone]

Fax: [phone]

Email: [e-mail]

(C) 2022 Electronic News Publishing, source ENP Newswire